Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors

ObjectiveThis study aims to evaluate the hemorrhage risk in solid tumor patients receiving angiogenesis inhibitors (AGIs), immune checkpoint inhibitors (ICIs), and their combination using the FDA Adverse Event Reporting System (FAERS) database.MethodsData from Q1 2011 to Q4 2023 were extracted from...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhui Yang, Pingping Long, Ying Tuo, Xiaoxiao Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitors
angiogenesis inhibitors
FDA adverse event reporting system (FAERS)
hemorrhagic risks
cancer therapy
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1527570/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items